Jideytro Approved for Previously Treated ROS1-Positive NSCLC

Originally published by our sister publication Clinical Oncology NewsBy Sarah TilyouThe FDA approved zidesamtinib (Jideytro, GlaxoSmithKline) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received at least one prior ROS1 tyrosine kinase inhibitor (TKI).figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block